Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities
The clinical and public health utility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serologic testing requires a better understanding of the dynamics of the humoral response to infection. To track seroconversion of IgG and IgM antibodies in patients with SARS-CoV-2 infection and i...
Gespeichert in:
| Veröffentlicht in: | Diagnostic microbiology and infectious disease 2021-04, Vol.99 (4), p.115300-115300, Article 115300 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 115300 |
|---|---|
| container_issue | 4 |
| container_start_page | 115300 |
| container_title | Diagnostic microbiology and infectious disease |
| container_volume | 99 |
| creator | Orner, Erika P Rodgers, Mary A Hock, Karl Tang, Mei San Taylor, Russell Gardiner, Mary Olivo, Ana Fox, Amy Prostko, John Cloherty, Gavin Farnsworth, Christopher W. |
| description | The clinical and public health utility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serologic testing requires a better understanding of the dynamics of the humoral response to infection. To track seroconversion of IgG and IgM antibodies in patients with SARS-CoV-2 infection and its association with patient and clinical factors and outcomes. Residual patient specimens were analyzed on the Abbott ARCHITECT i2000 instrument using the Abbott SARS-CoV-2 IgG assay and prototype SARS-CoV-2 IgM assay. Age, sex, comorbidities, symptom onset date, mortality, and specimen collection date were obtained from electronic medical records. Three hundred fifty-nine longitudinal samples were collected from 89 hospitalized patients 0 to 82 days postsymptom onset. Of all, 51.7% of the patients developed IgG and IgM antibodies simultaneously; 32.8% seroconverted for IgM before IgG. On average, patients seroconverted for IgG by 8 days and for IgM by 7 days postsymptom onset. All patients achieved IgG seropositivity by 19 days and IgM seropositivity by 17 days. Median time to IgG and IgM seroconversion was prolonged and initial levels of IgG were lower in immunocompromised patients and patients |
| doi_str_mv | 10.1016/j.diagmicrobio.2020.115300 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7759125</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0732889320306775</els_id><sourcerecordid>2475088054</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5250-ce2b8ea78117c0f43de978b0c857cde89e9372d719ed6dc7c04882875fcfa21d3</originalsourceid><addsrcrecordid>eNqNkUFv1DAQhS0EokvhLyCLE5csYyeuHQ5I1QKlUhESS7laXnuynVUSBzu7CH49rrZU5cZppJk3b57mY-yVgKUAcfZmtwzktgP5FDcUlxJkGQhVAzxiC2F0WwFoeMwWoGtZGdPWJ-xZzjsAIdsGnrKTuq6NUVotGK3iMLlEOY48dnx9_nVdreL3SvLL7WfuxlDqBc-Yoo_jAVOmIpxS7KjHzN0Qxy2_iXmi2fX0GwOf3Ew4zpnTyOefkV-vuafSys_Zk871GV_c1VN2_fHDt9Wn6urLxeXq_KrySiqoPMqNQaeNENpD19QBW2024EteH9C02NZaBi1aDGfBF01jjDRadb5zUoT6lL07-k77zYDBlzDJ9XZKNLj0y0ZH9t_JSDd2Gw9Wa9UKqYrB6zuDFH_sMc92oOyx792IcZ-tbLQCY0A1Rfr2KC0ock7Y3Z8RYG9Z2Z19yMresrJHVmX55cOg96t_4RTB-6MAy7sOhMlmX37rMVBCP9sQ6X_u_AF6Sa3M</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2475088054</pqid></control><display><type>article</type><title>Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Orner, Erika P ; Rodgers, Mary A ; Hock, Karl ; Tang, Mei San ; Taylor, Russell ; Gardiner, Mary ; Olivo, Ana ; Fox, Amy ; Prostko, John ; Cloherty, Gavin ; Farnsworth, Christopher W.</creator><creatorcontrib>Orner, Erika P ; Rodgers, Mary A ; Hock, Karl ; Tang, Mei San ; Taylor, Russell ; Gardiner, Mary ; Olivo, Ana ; Fox, Amy ; Prostko, John ; Cloherty, Gavin ; Farnsworth, Christopher W.</creatorcontrib><description>The clinical and public health utility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serologic testing requires a better understanding of the dynamics of the humoral response to infection. To track seroconversion of IgG and IgM antibodies in patients with SARS-CoV-2 infection and its association with patient and clinical factors and outcomes. Residual patient specimens were analyzed on the Abbott ARCHITECT i2000 instrument using the Abbott SARS-CoV-2 IgG assay and prototype SARS-CoV-2 IgM assay. Age, sex, comorbidities, symptom onset date, mortality, and specimen collection date were obtained from electronic medical records. Three hundred fifty-nine longitudinal samples were collected from 89 hospitalized patients 0 to 82 days postsymptom onset. Of all, 51.7% of the patients developed IgG and IgM antibodies simultaneously; 32.8% seroconverted for IgM before IgG. On average, patients seroconverted for IgG by 8 days and for IgM by 7 days postsymptom onset. All patients achieved IgG seropositivity by 19 days and IgM seropositivity by 17 days. Median time to IgG and IgM seroconversion was prolonged and initial levels of IgG were lower in immunocompromised patients and patients <65 years of age compared to immune competent patients and those ≥65 years of age. Immunocompromised patients also had persistently lower levels of IgM that peaked on day 17.6 and decreased thereafter compared to immune competent patients. IgM seroconversion in patients who died reached significantly higher levels later after symptom onset than in those who recovered. SARS-CoV-2 infected patients have similar time to seroconversion for IgG and IgM. However, differences in immune status and age alter time to seroconversion. These results may help guide serologic testing application in COVID-19 management.</description><identifier>ISSN: 0732-8893</identifier><identifier>EISSN: 1879-0070</identifier><identifier>DOI: 10.1016/j.diagmicrobio.2020.115300</identifier><identifier>PMID: 33388575</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Viral - blood ; COVID-19 ; COVID-19 - diagnosis ; COVID-19 Serological Testing - methods ; Female ; Hospitalization ; Humans ; Humoral immune response ; Immunity, Humoral - immunology ; Immunoglobulin G - blood ; Immunoglobulin M - blood ; Longitudinal Studies ; Male ; Middle Aged ; SARS-CoV-2 - immunology ; SARS-CoV-2 serology ; Sensitivity and Specificity ; Seroconversion ; Serologic assay ; United States ; Young Adult</subject><ispartof>Diagnostic microbiology and infectious disease, 2021-04, Vol.99 (4), p.115300-115300, Article 115300</ispartof><rights>2020 Elsevier Inc.</rights><rights>Copyright © 2020 Elsevier Inc. All rights reserved.</rights><rights>2020 Elsevier Inc. All rights reserved. 2020 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5250-ce2b8ea78117c0f43de978b0c857cde89e9372d719ed6dc7c04882875fcfa21d3</citedby><cites>FETCH-LOGICAL-c5250-ce2b8ea78117c0f43de978b0c857cde89e9372d719ed6dc7c04882875fcfa21d3</cites><orcidid>0000-0001-7207-7515 ; 0000-0001-8815-8651 ; 0000-0002-6253-7298 ; 0000-0003-1966-837X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0732889320306775$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33388575$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Orner, Erika P</creatorcontrib><creatorcontrib>Rodgers, Mary A</creatorcontrib><creatorcontrib>Hock, Karl</creatorcontrib><creatorcontrib>Tang, Mei San</creatorcontrib><creatorcontrib>Taylor, Russell</creatorcontrib><creatorcontrib>Gardiner, Mary</creatorcontrib><creatorcontrib>Olivo, Ana</creatorcontrib><creatorcontrib>Fox, Amy</creatorcontrib><creatorcontrib>Prostko, John</creatorcontrib><creatorcontrib>Cloherty, Gavin</creatorcontrib><creatorcontrib>Farnsworth, Christopher W.</creatorcontrib><title>Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities</title><title>Diagnostic microbiology and infectious disease</title><addtitle>Diagn Microbiol Infect Dis</addtitle><description>The clinical and public health utility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serologic testing requires a better understanding of the dynamics of the humoral response to infection. To track seroconversion of IgG and IgM antibodies in patients with SARS-CoV-2 infection and its association with patient and clinical factors and outcomes. Residual patient specimens were analyzed on the Abbott ARCHITECT i2000 instrument using the Abbott SARS-CoV-2 IgG assay and prototype SARS-CoV-2 IgM assay. Age, sex, comorbidities, symptom onset date, mortality, and specimen collection date were obtained from electronic medical records. Three hundred fifty-nine longitudinal samples were collected from 89 hospitalized patients 0 to 82 days postsymptom onset. Of all, 51.7% of the patients developed IgG and IgM antibodies simultaneously; 32.8% seroconverted for IgM before IgG. On average, patients seroconverted for IgG by 8 days and for IgM by 7 days postsymptom onset. All patients achieved IgG seropositivity by 19 days and IgM seropositivity by 17 days. Median time to IgG and IgM seroconversion was prolonged and initial levels of IgG were lower in immunocompromised patients and patients <65 years of age compared to immune competent patients and those ≥65 years of age. Immunocompromised patients also had persistently lower levels of IgM that peaked on day 17.6 and decreased thereafter compared to immune competent patients. IgM seroconversion in patients who died reached significantly higher levels later after symptom onset than in those who recovered. SARS-CoV-2 infected patients have similar time to seroconversion for IgG and IgM. However, differences in immune status and age alter time to seroconversion. These results may help guide serologic testing application in COVID-19 management.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Viral - blood</subject><subject>COVID-19</subject><subject>COVID-19 - diagnosis</subject><subject>COVID-19 Serological Testing - methods</subject><subject>Female</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Humoral immune response</subject><subject>Immunity, Humoral - immunology</subject><subject>Immunoglobulin G - blood</subject><subject>Immunoglobulin M - blood</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Middle Aged</subject><subject>SARS-CoV-2 - immunology</subject><subject>SARS-CoV-2 serology</subject><subject>Sensitivity and Specificity</subject><subject>Seroconversion</subject><subject>Serologic assay</subject><subject>United States</subject><subject>Young Adult</subject><issn>0732-8893</issn><issn>1879-0070</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUFv1DAQhS0EokvhLyCLE5csYyeuHQ5I1QKlUhESS7laXnuynVUSBzu7CH49rrZU5cZppJk3b57mY-yVgKUAcfZmtwzktgP5FDcUlxJkGQhVAzxiC2F0WwFoeMwWoGtZGdPWJ-xZzjsAIdsGnrKTuq6NUVotGK3iMLlEOY48dnx9_nVdreL3SvLL7WfuxlDqBc-Yoo_jAVOmIpxS7KjHzN0Qxy2_iXmi2fX0GwOf3Ew4zpnTyOefkV-vuafSys_Zk871GV_c1VN2_fHDt9Wn6urLxeXq_KrySiqoPMqNQaeNENpD19QBW2024EteH9C02NZaBi1aDGfBF01jjDRadb5zUoT6lL07-k77zYDBlzDJ9XZKNLj0y0ZH9t_JSDd2Gw9Wa9UKqYrB6zuDFH_sMc92oOyx792IcZ-tbLQCY0A1Rfr2KC0ock7Y3Z8RYG9Z2Z19yMresrJHVmX55cOg96t_4RTB-6MAy7sOhMlmX37rMVBCP9sQ6X_u_AF6Sa3M</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Orner, Erika P</creator><creator>Rodgers, Mary A</creator><creator>Hock, Karl</creator><creator>Tang, Mei San</creator><creator>Taylor, Russell</creator><creator>Gardiner, Mary</creator><creator>Olivo, Ana</creator><creator>Fox, Amy</creator><creator>Prostko, John</creator><creator>Cloherty, Gavin</creator><creator>Farnsworth, Christopher W.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7207-7515</orcidid><orcidid>https://orcid.org/0000-0001-8815-8651</orcidid><orcidid>https://orcid.org/0000-0002-6253-7298</orcidid><orcidid>https://orcid.org/0000-0003-1966-837X</orcidid></search><sort><creationdate>20210401</creationdate><title>Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities</title><author>Orner, Erika P ; Rodgers, Mary A ; Hock, Karl ; Tang, Mei San ; Taylor, Russell ; Gardiner, Mary ; Olivo, Ana ; Fox, Amy ; Prostko, John ; Cloherty, Gavin ; Farnsworth, Christopher W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5250-ce2b8ea78117c0f43de978b0c857cde89e9372d719ed6dc7c04882875fcfa21d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Viral - blood</topic><topic>COVID-19</topic><topic>COVID-19 - diagnosis</topic><topic>COVID-19 Serological Testing - methods</topic><topic>Female</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Humoral immune response</topic><topic>Immunity, Humoral - immunology</topic><topic>Immunoglobulin G - blood</topic><topic>Immunoglobulin M - blood</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Middle Aged</topic><topic>SARS-CoV-2 - immunology</topic><topic>SARS-CoV-2 serology</topic><topic>Sensitivity and Specificity</topic><topic>Seroconversion</topic><topic>Serologic assay</topic><topic>United States</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Orner, Erika P</creatorcontrib><creatorcontrib>Rodgers, Mary A</creatorcontrib><creatorcontrib>Hock, Karl</creatorcontrib><creatorcontrib>Tang, Mei San</creatorcontrib><creatorcontrib>Taylor, Russell</creatorcontrib><creatorcontrib>Gardiner, Mary</creatorcontrib><creatorcontrib>Olivo, Ana</creatorcontrib><creatorcontrib>Fox, Amy</creatorcontrib><creatorcontrib>Prostko, John</creatorcontrib><creatorcontrib>Cloherty, Gavin</creatorcontrib><creatorcontrib>Farnsworth, Christopher W.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diagnostic microbiology and infectious disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Orner, Erika P</au><au>Rodgers, Mary A</au><au>Hock, Karl</au><au>Tang, Mei San</au><au>Taylor, Russell</au><au>Gardiner, Mary</au><au>Olivo, Ana</au><au>Fox, Amy</au><au>Prostko, John</au><au>Cloherty, Gavin</au><au>Farnsworth, Christopher W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities</atitle><jtitle>Diagnostic microbiology and infectious disease</jtitle><addtitle>Diagn Microbiol Infect Dis</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>99</volume><issue>4</issue><spage>115300</spage><epage>115300</epage><pages>115300-115300</pages><artnum>115300</artnum><issn>0732-8893</issn><eissn>1879-0070</eissn><abstract>The clinical and public health utility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serologic testing requires a better understanding of the dynamics of the humoral response to infection. To track seroconversion of IgG and IgM antibodies in patients with SARS-CoV-2 infection and its association with patient and clinical factors and outcomes. Residual patient specimens were analyzed on the Abbott ARCHITECT i2000 instrument using the Abbott SARS-CoV-2 IgG assay and prototype SARS-CoV-2 IgM assay. Age, sex, comorbidities, symptom onset date, mortality, and specimen collection date were obtained from electronic medical records. Three hundred fifty-nine longitudinal samples were collected from 89 hospitalized patients 0 to 82 days postsymptom onset. Of all, 51.7% of the patients developed IgG and IgM antibodies simultaneously; 32.8% seroconverted for IgM before IgG. On average, patients seroconverted for IgG by 8 days and for IgM by 7 days postsymptom onset. All patients achieved IgG seropositivity by 19 days and IgM seropositivity by 17 days. Median time to IgG and IgM seroconversion was prolonged and initial levels of IgG were lower in immunocompromised patients and patients <65 years of age compared to immune competent patients and those ≥65 years of age. Immunocompromised patients also had persistently lower levels of IgM that peaked on day 17.6 and decreased thereafter compared to immune competent patients. IgM seroconversion in patients who died reached significantly higher levels later after symptom onset than in those who recovered. SARS-CoV-2 infected patients have similar time to seroconversion for IgG and IgM. However, differences in immune status and age alter time to seroconversion. These results may help guide serologic testing application in COVID-19 management.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33388575</pmid><doi>10.1016/j.diagmicrobio.2020.115300</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-7207-7515</orcidid><orcidid>https://orcid.org/0000-0001-8815-8651</orcidid><orcidid>https://orcid.org/0000-0002-6253-7298</orcidid><orcidid>https://orcid.org/0000-0003-1966-837X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-8893 |
| ispartof | Diagnostic microbiology and infectious disease, 2021-04, Vol.99 (4), p.115300-115300, Article 115300 |
| issn | 0732-8893 1879-0070 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7759125 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adolescent Adult Aged Aged, 80 and over Antibodies, Viral - blood COVID-19 COVID-19 - diagnosis COVID-19 Serological Testing - methods Female Hospitalization Humans Humoral immune response Immunity, Humoral - immunology Immunoglobulin G - blood Immunoglobulin M - blood Longitudinal Studies Male Middle Aged SARS-CoV-2 - immunology SARS-CoV-2 serology Sensitivity and Specificity Seroconversion Serologic assay United States Young Adult |
| title | Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T00%3A16%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20SARS-CoV-2%20IgM%20and%20IgG%20seroconversion%20profiles%20among%20hospitalized%20patients%20in%20two%20US%20cities&rft.jtitle=Diagnostic%20microbiology%20and%20infectious%20disease&rft.au=Orner,%20Erika%20P&rft.date=2021-04-01&rft.volume=99&rft.issue=4&rft.spage=115300&rft.epage=115300&rft.pages=115300-115300&rft.artnum=115300&rft.issn=0732-8893&rft.eissn=1879-0070&rft_id=info:doi/10.1016/j.diagmicrobio.2020.115300&rft_dat=%3Cproquest_pubme%3E2475088054%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2475088054&rft_id=info:pmid/33388575&rft_els_id=S0732889320306775&rfr_iscdi=true |